David Vyles1, Asriani Chiu2, John Routes2, Mariana Castells3, Elizabeth J Phillips4, Jennifer Kibicho5, David C Brousseau6. 1. Section of Pediatric Emergency Medicine and dvyles@mcw.edu. 2. Division of Allergy and Immunology, Medical College of Wisconsin, Milwaukee, Wisconsin. 3. Division of Rheumatology, Immunology and Allergy, Harvard Medical School, Harvard University and Brigham and Women's Hospital, Boston, Massachusetts. 4. Department of Medicine, School of Medicine, Vanderbilt University, Nashville, Tennessee; and. 5. College of Nursing, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin. 6. Section of Pediatric Emergency Medicine and.
Abstract
BACKGROUND: Penicillin allergy is commonly reported in the pediatric emergency department. We previously performed 3-tier penicillin allergy testing on children with low-risk symptoms, and 100% tolerated a penicillin challenge without an allergic reaction. We hypothesized that no serious allergic reactions would occur after re-exposure to penicillin and that prescription practices would change after testing. METHODS: We performed a follow-up case series of 100 children whose test results were negative for penicillin allergy. Research staff administered a brief follow-up phone survey to the parent and primary care provider of each patient tested. We combined the survey data and summarized baseline patient characteristics and questionnaire responses. We then completed a 3-tier economic analysis from the prescription information gathered from surveys in which cost savings, cost avoidance, and potential cost savings were calculated. RESULTS: A total of 46 prescriptions in 36 patients were reported by the primary care provider and/or parents within the year after patients were tested for penicillin allergy. Twenty-six (58%) of the prescriptions filled were penicillin derivatives. One (4%) child developed a rash 24 hours after starting the medication; no child developed a serious adverse reaction after being given a penicillin challenge. We found that the cost savings of delabeling patients as penicillin allergic was $1368.13, the cost avoidance was $1812.00, and the total potential cost savings for the pediatric emergency department population was $192 223.00. CONCLUSIONS: Children with low-risk penicillin allergy symptoms whose test results were negative for penicillin allergy tolerated a penicillin challenge without a severe allergic reaction developing. Delabeling children changed prescription behavior and led to actual health care savings.
BACKGROUND:Penicillinallergy is commonly reported in the pediatric emergency department. We previously performed 3-tier penicillinallergy testing on children with low-risk symptoms, and 100% tolerated a penicillin challenge without an allergic reaction. We hypothesized that no serious allergic reactions would occur after re-exposure to penicillin and that prescription practices would change after testing. METHODS: We performed a follow-up case series of 100 children whose test results were negative for penicillinallergy. Research staff administered a brief follow-up phone survey to the parent and primary care provider of each patient tested. We combined the survey data and summarized baseline patient characteristics and questionnaire responses. We then completed a 3-tier economic analysis from the prescription information gathered from surveys in which cost savings, cost avoidance, and potential cost savings were calculated. RESULTS: A total of 46 prescriptions in 36 patients were reported by the primary care provider and/or parents within the year after patients were tested for penicillinallergy. Twenty-six (58%) of the prescriptions filled were penicillin derivatives. One (4%) child developed a rash 24 hours after starting the medication; no child developed a serious adverse reaction after being given a penicillin challenge. We found that the cost savings of delabeling patients as penicillin allergic was $1368.13, the cost avoidance was $1812.00, and the total potential cost savings for the pediatric emergency department population was $192 223.00. CONCLUSIONS:Children with low-risk penicillinallergy symptoms whose test results were negative for penicillinallergy tolerated a penicillin challenge without a severe allergic reaction developing. Delabeling children changed prescription behavior and led to actual health care savings.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: D D Sogn; R Evans; G M Shepherd; T B Casale; J Condemi; P A Greenberger; P F Kohler; A Saxon; R J Summers; P P VanArsdel Journal: Arch Intern Med Date: 1992-05
Authors: David Vyles; Asriani Chiu; Pippa Simpson; Mark Nimmer; Juan Adams; David C Brousseau Journal: Acad Pediatr Date: 2017-03-06 Impact factor: 3.107
Authors: David Vyles; Juan Adams; Asriani Chiu; Pippa Simpson; Mark Nimmer; David C Brousseau Journal: Pediatrics Date: 2017-07-03 Impact factor: 7.124
Authors: Mustafa Ozkaynak; Noel Metcalf; Daniel M Cohen; Larissa S May; Peter S Dayan; Rakesh D Mistry Journal: Appl Clin Inform Date: 2020-09-09 Impact factor: 2.342
Authors: Cosby A Stone; Jason Trubiano; David T Coleman; Christine R F Rukasin; Elizabeth J Phillips Journal: Allergy Date: 2019-05-26 Impact factor: 13.146
Authors: Mary L Staicu; David Vyles; Erica S Shenoy; Cosby A Stone; Taylor Banks; Kristin S Alvarez; Kimberly G Blumenthal Journal: J Allergy Clin Immunol Pract Date: 2020-10
Authors: James W Antoon; Carlos G Grijalva; Alison G Grisso; Cosby A Stone; Jakobi Johnson; Justine Stassun; Allison E Norton; Sunil Kripalani; Derek J Williams Journal: Hosp Pediatr Date: 2022-07-01
Authors: David Vyles; James W Antoon; Allison Norton; Cosby A Stone; Jason Trubiano; Alexandra Radowicz; Elizabeth J Phillips Journal: Ann Allergy Asthma Immunol Date: 2020-03-26 Impact factor: 6.347
Authors: Hannah Imlay; Elizabeth M Krantz; Erica J Stohs; Kristine F Lan; Jacqlynn Zier; H Nina Kim; Robert M Rakita; Ajit P Limaye; Anna Wald; Steven A Pergam; Catherine Liu Journal: Clin Infect Dis Date: 2020-10-23 Impact factor: 20.999
Authors: Marta Wanat; Sibyl Anthierens; Christopher C Butler; Judy M Wright; Naila Dracup; Sue H Pavitt; Jonathan A T Sandoe; Sarah Tonkin-Crine Journal: Antibiotics (Basel) Date: 2018-08-06